“In 1983, Amos Tversky and Daniel Kahneman published a six-page paper in Psychological Review with one of the most counter-intuitive results in cognitive psychology: when given a detailed description of a fictional woman named Linda, 85% of educated participants — including statistics PhDs — judged the more specific, more detailed statement to be more probable than the less specific one. This was a logical impossibility. The probability of A AND B can never exceed the probability of A alone. Yet the human mind, in its hunt for coherent narrative, reliably overrides the basic axioms of probability. The investing world is full of Lindas dressed as stock theses.”
1. The Bias — What the Conjunction Fallacy Actually Is
The Conjunction Fallacy is the cognitive error of judging a conjoint event (A and B) as more likely than one of its constituent events (A alone). Formally, for any two events A and B, the probability axiom requires:
P(A ∩ B) ≤ P(A)
This holds without exception, regardless of how compelling the joint story sounds. Tversky and Kahneman’s landmark 1983 paper — “Extensional versus Intuitive Reasoning: The Conjunction Fallacy in Probability Judgment”, Psychological Review, 90(4), 293-315 — showed that subjects systematically violate this inequality whenever the conjoint event is delivered as a coherent story. The famous example used a fictional character named Linda:
“Linda is 31 years old, single, outspoken, and very bright. She majored in philosophy. As a student, she was deeply concerned with issues of discrimination and social justice, and also participated in anti-nuclear demonstrations.”
Which is more probable?
- Linda is a bank teller.
- Linda is a bank teller and is active in the feminist movement.
85% of participants chose option (b), even though (b) is a subset of (a) and therefore cannot be more probable. The detail “feminist movement” added explanatory richness — and the brain, hungry for narrative fit, mistook fit for probability.
2. The Underlying Psychology — Why the Mind Confuses Coherence with Probability
Tversky and Kahneman attributed the fallacy to the representativeness heuristic — people judge probability by how closely a description matches a stereotype, not by how often the event actually occurs. A coherent multi-leg story feels representative of the world; a single bare statement does not. So the brain quietly substitutes the easier question (“How well does this story fit my mental picture?”) for the harder one (“How often does this combination of events actually happen?”).
Daniel Kahneman, writing in Thinking, Fast and Slow (2011, Chapter 15), summarised the takeaway in one sentence: “Adding detail to scenarios makes them more persuasive, but less likely to be true.” The more conditions a bull thesis bolts on — a new product launch, plus an export tailwind, plus margin expansion, plus a re-rating multiple, plus a credit-rating upgrade, plus a promoter buyback — the lower the joint probability, and the higher the perceived plausibility. This is precisely the inversion that destroys retail-investor capital.
3. The Indian Manifestation — Where the Conjunction Fallacy Shows Up on Dalal Street
India’s retail investor base — which grew from 4.1 crore demat accounts in March 2020 to roughly 18 crore by March 2026 per NSDL-CDSL data — has been fed a near-constant diet of multi-leg bull stories on YouTube, X, Telegram and television. Three settings where the conjunction fallacy is at its most expensive:
Setting 1 — The “five-leg” YouTube bull thesis. A typical 22-minute video walks through five sequential and-statements: “The company is launching a new product (A) and exports will grow (B) and margins will expand (C) and the PE will re-rate (D) and the promoter will increase his stake (E).” Each individual claim might have, say, a 60% chance. The joint probability — if the events were independent — is 0.65 = 7.8%. Yet retail viewers consistently rate the five-leg story as more likely to play out than the same company’s one-leg thesis. SEBI’s 2024 study on retail F&O traders showed that 93% of individual F&O traders lost money in FY24, with aggregate net losses of ₹1.81 lakh crore — much of which was capital wagered on conjunctive “everything must go right” scenarios.
Setting 2 — The IPO prospectus. Indian draft red herring prospectuses (DRHPs) routinely contain seven-leg “future strategy” sections — geographic expansion, vertical integration, premiumisation, capacity addition, digital transformation, ESG positioning, M&A optionality. Each leg individually may be reasonable. Strung together, they ask the investor to bet on a conjunction whose joint probability is vanishingly small. A SEBI 2024 study covering 144 IPOs listed between FY22 and FY24 showed that 50% of allotted shares were sold within one week of listing — retail investors voting with their feet once the multi-leg story collided with single-quarter results.
Setting 3 — The PMS pitch deck. Portfolio Management Schemes in India routinely market themselves with claims like: “Our process identifies companies that have (i) low debt, (ii) high ROCE, (iii) management integrity, (iv) a moat, (v) mispricing, (vi) a catalyst within 12 months, (vii) sector tailwinds, and (viii) promoter skin in the game.” The list reads as a thesis. It is, in fact, a near-impossible conjunction, and SEBI’s 2024 PMS-disclosure data shows that the median PMS strategy underperforms the Nifty 500 Total Returns Index over 5-year rolling windows precisely because the eight-leg filter forces the manager to accept low base-rate setups dressed as high-probability composite stories.
Prof. V. Ravi Anshuman at IIM Bangalore, in his lecture series on behavioural finance, has called this the “compounded-story illusion” — investors who would never buy an unlikely event in isolation cheerfully buy a basket of seven of them so long as a 60-minute video weaves them into a single arc.
4. The Counter-Measure — A Conjunction-Fallacy Checklist for the Indian Long-Term Investor
The defence is not to avoid stories. It is to decompose them and price each leg independently before re-multiplying.
- List every “and” in the thesis. Underline every conjunction. A six-leg thesis has six conjunctions. Each one is a probabilistic toll booth.
- Assign a base-rate probability to each leg. Use historical Indian data wherever possible — what percentage of mid-cap pharma companies actually expand EBITDA margins by 200 bps over three years? Not 95%. Closer to 25% per SEBI’s 2024 sector studies.
- Multiply the legs. If you have five legs at 60% each, the joint probability is under 8%. If you have eight legs at 50% each, the joint probability is 0.4%. This is the actual probability your thesis plays out — not the gut feel from the narrator’s voice.
- Compare to base rates. Historic Indian data from CRISIL and Prime Database shows that, on a 5-year rolling window, roughly 4–6% of listed Indian small-caps deliver 5x or better. Any thesis whose decomposed probability is materially higher than 6% should be re-examined for conjunction-fallacy inflation.
- Prefer one-leg theses. The classic value-investing thesis is a single sentence: “This business compounds free cash flow at a sustainable rate.” One conjunction, one probability. Many of Buffett’s largest positions — Coca-Cola, See’s Candies, Apple — were originally single-leg theses dressed up only much later by commentators.
- Write the inverse story. Pre-mortem each leg. If leg 3 fails, does the thesis survive? If the answer is no, the thesis is conjunctive. If the answer is yes, the thesis is robust.
- Decision-journal the decomposition. Annie Duke’s discipline from Thinking in Bets (2018) — write down the joint probability before buying. Re-read 12 months later. The gap between perceived joint probability and realised outcome is the bias bill.
5. How Graham, Buffett, Munger and Klarman Addressed the Conjunction Fallacy
Benjamin Graham (Security Analysis, 1934 and The Intelligent Investor, 1949) reduced the entire stock-picking exercise to two questions: (i) is the business sound, and (ii) is the price at a sufficient discount to conservative intrinsic value? Two legs. No bolt-on conjunctions. Graham’s “Mr Market” allegory was a deliberate refusal to add narrative layers to what was, at its core, a single decision: buy below intrinsic value, sell above it.
Warren Buffett (1977 Berkshire letter onward) compressed his acquisition criteria to four filters — competence, durability, honesty, price — and explicitly warned in his 1996 letter against “the inevitables” trap, where investors mistake a coherent narrative (“everything must go right and probably will”) for a probabilistic forecast. Buffett’s Mr Market metaphor and his oft-quoted preference for “wonderful businesses at fair prices” rather than “fair businesses at wonderful prices” is a deliberate refusal to compound assumptions. He prefers one strong leg over five mediocre ones.
Charlie Munger (1995 Harvard Speech, “The Psychology of Human Misjudgment”) named “twaddle tendency” and “reason-respecting tendency” as cognitive cousins of the conjunction fallacy. His prescription was the inversion mental model — “tell me where I’ll die so I never go there” — which directly attacks conjunctive theses by asking which legs must fail. If even one critical leg can fail, the joint probability is set by the weakest link, not the average.
Seth Klarman (Margin of Safety, 1991) framed it as a discipline of “three pillars”: bottom-up fundamental analysis, absolute (not relative) return targets, and risk-aversion-first thinking. Each pillar is a constraint, not a conjunction. Klarman insists that a thesis should survive the failure of any one assumption — which is the operational opposite of a multi-leg bull story where the failure of one leg destroys the whole edifice.
6. Illustrative Case — How Titan Biotech Ltd (BSE: 524717) Exhibits Single-Leg Thesis Discipline in Corporate Behaviour
This section is an educational case study of management process and audited corporate-behavioural markers. It is NOT a valuation call. It is NOT a buy/sell/hold recommendation. No price target, intrinsic value, or fair-value assessment of Titan Biotech is offered or implied.
The relevant question is not whether Titan Biotech is “cheap” or “expensive” — that is not what this article is about. The relevant question is: does the company’s disclosed corporate behaviour read like a one-leg compounding thesis (the Graham-Buffett-Klarman frame) or like a seven-leg conjunctive bull story (the YouTube/PMS frame)? The audited numbers below let the reader judge for themselves.
Marker → Number → Behavioural Interpretation
| Behavioural marker | Audited FY25 number | Single-leg interpretation |
|---|---|---|
| 10-year sales CAGR | 15% | A single, sustained top-line leg — no episodic “one-off” narrative. |
| 10-year profit CAGR | 29% | Operating leverage emerging from one core business, not seven bolt-ons. |
| FY25 ROCE | 16.9% | Capital efficiency above the cost of capital from existing assets — not contingent on a future re-rating. |
| FY25 borrowings | ₹3 crore (down from ₹16 Cr in FY21, −81%) | Solvency leg is essentially absent as a risk — one fewer conjunction to worry about. |
| FY25 contingent liabilities | ₹7.78 crore (−39.7% YoY; 5.08% of net worth) | Off-balance-sheet conjunctive tail risks are shrinking, not expanding. |
| CFO / Operating Profit (FY25) | 103% | Reported profit converts to cash without requiring a “and-then-receivables-collapse” conjunction. |
| Three consecutive QoQ revenue (FY26) | ₹46.5 Cr → ₹54 Cr → ₹56 Cr | Top-line behaviour is realising — not a multi-leg forecast. |
| Board independence | 4 of 11 directors independent (36.4%); 14 board meetings FY25; independent chair | Governance leg confirmed by Companies Act / LODR markers — not promised by narrative. |
| Export share of revenue | ~34.5% (Overseas ₹5,390.28 lakh; Domestic ₹10,254.80 lakh) | Geographic diversification is realised, not contingent on a “and global tailwinds materialise” leg. |
What this table is meant to illustrate — and only illustrate — is that Titan Biotech’s audited corporate-behavioural profile reads more like a Graham/Buffett single-leg thesis (“a business is steadily compounding from existing assets”) than a YouTube-style seven-leg conjunctive bull story. The behavioural interpretation is independent of any view on the share price, the market capitalisation, or the future trajectory of the stock.
Put differently: a hypothetical investor decomposing a thesis on Titan Biotech using the seven-step conjunction-fallacy checklist would find fewer conjunctions than in a typical IPO prospectus or PMS pitch deck. That is a statement about process, not about valuation. The reader’s own valuation work, conducted by a SEBI-registered investment advisor or via independent research, remains a separate exercise.
7. Key Takeaways
- The conjunction fallacy is a probability axiom violation, not just a “bad feeling”. P(A ∩ B) cannot exceed P(A). If your stock thesis depends on five things going right, the probability of all five is multiplicative — not additive.
- Detail feels like evidence, but is the opposite of probability. Every and in a bull thesis lowers the joint probability while raising the perceived plausibility — the inversion that Tversky and Kahneman documented in 1983.
- Indian retail data confirms the bias is expensive. SEBI’s 2024 F&O study (₹1.81 lakh crore aggregate retail losses; 93% loss-making) is a financial map of multi-leg conjunctive bets dressed as confidence trades.
- Decompose, multiply, compare to base rates. Apply the seven-step counter-measure to every thesis. The number you compute is the actual probability your story plays out.
- Prefer single-leg theses. Graham (two filters), Buffett (four filters), Munger (inversion), and Klarman (three pillars) all share an aversion to high-conjunction stories. Operationally, Titan Biotech’s audited FY25 profile — 10-year sales CAGR 15%, profit CAGR 29%, ROCE 16.9%, borrowings down to ₹3 Cr (−81% from FY21), CFO/OP 103%, three consecutive QoQ revenue prints — reads as one compounding leg rather than seven bolted-on legs, which is an educational illustration of single-leg corporate behaviour, NOT a valuation call.
- Process > outcome. Annie Duke’s discipline of writing down joint probabilities before buying, then journalling outcomes, is the practical antidote.
Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.
